Europe Insulin Infusion Pumps - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

The Europe Insulin Infusion Pumps Market size is estimated at USD 559.05 million in 2024, and is expected to reach USD 675.26 million by 2029, growing at a CAGR of 3.85% during the forecast period (2024-2029).

The COVID-19 pandemic has had a significant impact on the market studied. Type-1 diabetes patients have been more affected during the pandemic since people with diabetes have weak immune systems. People with diabetes are also more likely to face serious complications than normal people. The estimated cost per hospital admission during the first wave of COVID-19 in Europe ranged from EUR 25,018 for Type 2 diabetes patients with good glycemic control to EUR 57,244 for Type 1 diabetes patients with poor glycemic control. This reflects a higher risk of intensive care and ventilator support and a longer hospital stay. The estimated cost for patients without diabetes was EUR 16,993. The estimated total direct expenditure for secondary care for COVID-19 in Europe was EUR 13.9 billion. Therefore, diabetes treatment accounted for 23.5% of the total expenditures.

An insulin pump (also known as continuous subcutaneous insulin therapy) is a medical device used for the administration of insulin in the treatment of diabetes. Insulin pumps make it possible to deliver continuous infusion amounts of insulin at regular intervals. This is predicted to result in long-term cost savings relative to multiple daily injections. A conventional insulin pump includes the pump (including controls, a processing module, and batteries), a disposable reservoir for insulin (inside the pump), and a disposable infusion set, including a cannula for subcutaneous (under the skin) insertion and a tubing system to connect the insulin reservoir to the cannula. The configuration of the device may vary depending on the design. However, the application of infusion pumps across the world is increasing significantly.

Europe Insulin Infusion Pumps Market Trends

Insulin Pump Monitors Hold Largest Market Share

Countries in Europe are facing a high burden of diabetes expenditures. According to the IDF, the overall diabetes expenditure in Europe among the population aged 20-79 years was USD 156 billion, and it is expected to increase to USD 174 billion by 2040. According to the same source, 21,600 children are added to the type-1 diabetic population every year. These figures indicate that approximately 9% of the total healthcare expenditure in Europe is spent on diabetes. For patients relying on insulin pumps or multiple daily injections (MDI), CGM systems are an effective tool. They help in the improvement of glycemic balance without aggravating the danger of severe hypoglycemia.

In Europe, a variety of insulin pumps are available. Conventional insulin pumps have an insulin reservoir (or container) and a pumping mechanism attached to the body with tubing and an infusion set. Other insulin patch pumps are worn directly on the body and have a reservoir, pumping mechanism, and infusion set inside a small case. A separate device that allows for the programming of insulin delivery from the patch controls patch pumps wirelessly. Most insurance companies in Europe cover insulin pump therapy with variable out-of-pocket expenses.

The technology associated with insulin pumps combines glucose monitoring using CGM with advanced algorithms to predict low glucose and suspend insulin delivery. The technological innovation in the insulin pump market is likely to drive the market during the forecast period.

Germany Holds the Highest Market Share

A study conducted in July 2020 in Germany found a significant increase in diabetic ketoacidosis and severe ketoacidosis in diabetes diagnoses in children and adolescents during the COVID-19 pandemic. The underlying causes for this increase could be multifactorial and reflect reduced medical services, fear of approaching the healthcare system, and other complex psychosocial factors. The German Center for Diabetes Research (DZD) conducts extensive scientific research to develop effective prevention and treatment measures to prevent the emergence or progression of diabetes. Around 11% of the people living in Germany have private health insurance. Only people who fulfill certain criteria can have private health insurance. For example, the gross income of the person seeking insurance must have been above a certain threshold for at least one year. The developments in the insulin infusion pump reimbursement field are expected to bolster the adoption of insulin infusion pumps in Germany. At least 7.2 percent of the population in Germany currently has diabetes, the majority of which is type-2 diabetes, depending on the estimate. Over the next 20 years, there can be a huge rise in the number of diabetics. Up to 12 million individuals in Germany could have type-2 diabetes in 20 years, according to researchers from the Robert Koch Institute (RKI) in Berlin and the German Diabetes Center (DDZ) in Düsseldorf. From 2015 to 2040, this is expected to represent an increase of up to 77%. The DDZ scientists and their colleagues from the RKI published for the first time comprehensive projections of the future number of type-2 diabetes cases in Germany for all age groups based on the data of approximately 65 million subscribers to the German statutory health insurance and the Federal Statistical Office. They factored in current developments regarding newly diagnosed cases, rising life expectancy, and declining mortality rates as a result of medical advancements while calculating the development of case numbers between 2015 and 2040.

Europe Insulin Infusion Pumps Industry Overview

The new technologies in insulin infusion pump devices have driven the market study. Animas had to exit the insulin pump market due to rising competition. Medtronic is the market leader and is expected to maintain its position during the forecast period.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.